Good morning, everyone. Thank you for joining today's call. My name is Priscilla Kazumba. I will be your moderator today. We have changed the format of our presentation. I hope you will enjoy it. Today's webcast is presented to you by Tim Thurn, our CEO, and Henrik Bergentoft, the CFO. The presentation will address the first quarter of the fiscal year 2021, but also the CEO speech as part of our virtual annual general meeting. In the first part, Tim will give a short introduction and comment on the financial highlights of Q1, followed by an analysis of the sales development before he finishes with commenting on the key events. Henrik will guide you through the financial review before he hands over the microphone to Tim, who will wrap up the year 2020. We have also changed the format of our Q&A session. In case you wish to ask question, please press the raise your hand button. It's a yellow button with a hand, and I will open the microphone at the end of the presentation. If you wish to access the presentation later on, a recording of the webcast will be available on the C-RAD website after the presentation. Therewith, I hand over the microphone to Tim. Perfect, Priscilla. Thank you very much. Let's get started with an introduction and the financial highlights. C-RAD is active in the field of cancer treatment. Our customers are hospitals that fight cancer with radiation. In modern high precision radiation therapy, accurate tumor alignment is crucial for a safe and successful treatment. C-RAD positioning products are supporting this process and are fully integrated in the clinical workflow. Over the past years, C-RAD has been growing significantly and generated last year SEK 200 million in revenue and an operating profit of approximately SEK 17 million. The revenue growth, combined with marginal cost increases, deliver a record high first quarter operating profit for the company. Let's take a closer look. We are starting the year with an order intake of SEK 66.3 million. This is reflecting a growth of 39% or 49% in constant currencies year-on-year. Revenue amounted to SEK 60.0 million, reflecting a growth of 16% or 23% in constant currencies compared to the first quarter 2020. Due to COVID, deliveries to various countries were somewhat restricted last year. As a consequence, order backlog grew by 30%. With a stable cost base compared to previous year, we are delivering an operating profit of SEK 6.2 million during the first quarter, corresponding to a margin of 10.4%. This is a very positive development and underlines the demand of our technology in advanced radiation therapy. Let's take a closer look at our sales performance. We are starting off 2021 with another very solid quarter. The growth in order intake of almost 50% in constant currencies is very satisfying. Order intake continues to grow at high pace in all our product segments. The cooperation with Elekta in North America is developing well, and the region has achieved a strong recovery compared to last year. Both companies' teams are working tight together to develop the market and to present the combined value proposition to customers. The strong momentum in the APAC region, driven by the Chinese market, continues in the first quarter, reflected in order intake, but also in revenue. In the EMEA region, the purchasing behavior is still somewhat affected by COVID-19. Our business is subject to a distinct seasonality pattern, whereas usually the beginning of the year is weak and the second half, and especially the fourth quarter, is coming in very strong. This is affecting revenue, but even more order intake. COVID-19 is still affecting our business, but it is very encouraging to see that customers refocus on upgrading their cancer centers with surface tracking on the journey to establish our technology as the standard of care. The impact partly correlates with COVID-19 policies of the respective governments, but we also noted that the approval process for capital investments, both for private and governmental healthcare providers, became longer. Notwithstanding, we have a largely stable result both in order intake as in revenue within the regions. Very solid revenue growth. In the Americas, we see a decline due to the gravity of orders in the Americas during the last year being booked very late in the year. Very encouraging the continued dynamic in the APAC region. The service or life cycle business continues to grow at accelerated speed. The service agreements are usually long-term commitments from our customers to purchase services to the system. It's a great opportunity to build up and maintain a relationship with our customers beyond the initial product sale. With the implementation of vaccination programs progressing and COVID-19 related lethality going down, the focus in the healthcare sector is shifting back on cancer care. The clinical advantages of high precision radiation therapy are widely researched, and recent developments in the recent reimbursement systems in major markets enable customers to invest in required equipment to deliver safe and accurate radiation therapy for patients in need. I believe this slide is displaying a fantastic journey with surface tracking technology becoming standard of care in advanced radiation therapy. Coming to the key events during the period. The Patent and Market Court of Appeal issues a judgment confirming C-RAD's entitlement to Beamocular's invention. Therewith, the court is following largely C-RAD's claim. Parts of the invention originate from C-RAD. Certainly a success with, however, limited impact on our operation and the foreseeable business outlook. The invention is related to the GEMini product. C-RAD has ceased the development efforts in December 2019 related to this product. To sum up, we are excited by the results of our work and what we have achieved so far and look optimistically in the future. With that said, the market continues to be volatile and comes with a distinct seasonality pattern. This might have an impact on both order intake and revenue in individual quarters. I'm very confident about our mid and long-term opportunity. Thank you. Therewith, I hand over to Henrik, who will guide us through the financial review. Thank you, Tim. We'll start off with a closer look at our P&L statement, and as Tim already commented, we saw a revenue growth of 16% to SEK 60 million in the first quarter or in constant currency, a growth of 23%. The currency effect is much due to a stronger SEK versus the U.S. dollars in 2021 compared to 2020. APAC generates a growth of 74%, partly due to a weaker first quarter 2020 related to the pandemic, but mainly due to a long period of strong order intake that now converts into revenue. Revenue in Americas is decreasing due to the fact that order intake did not recover in the region until the end of 2020, and those orders are yet to be delivered and hence, not yet recognized as revenue. Revenue in EMEA generated a growth of 2%, if anything, signaling that despite pandemic challenges, deliveries and installations can still take place. Moving down, the gross profit margin was 61% during the first quarter 2021 compared to 58% last year. Our external expenses for the quarter amounted to SEK 12.8 million compared to SEK 11.4 million last year. Last year included a positive outcome in a court appeal on trade secrets, returning fees previously paid by the company amounting to some SEK 1.7 million. The underlying level of operating expenses are approximately in line with last year. With regards to personnel expenses, they amounted to SEK 16 million in the quarter. Last year, we also had a non-recurring item, a cost of approximately SEK 2 million related to changes in the executive team. The average numbers of employees amounted to 57 during the first quarter 2021 compared to 61 during the corresponding period in 2020. We end the quarter with 57 of employees compared to 63 last year. To sum it up, operating income for the quarter amounted to SEK 6.2 million compared to SEK 1 million last year, constituting a margin of 10.4% compared to 1.9% last year. The increase in the operating margin, an improved margin is a function of the growth in revenue with improved gross margins and only with a slight increase of our operating expenses. The net result of the tax in the quarter amounted to SEK 3.2 million compared to SEK 0.4 million last year. The tax expense that we account for in this quarter refers only to the reversal of the deferred tax asset related to Swedish entities. This has no impact on cash flow whatsoever, and we end the quarter with a total deferred tax asset of SEK 20.7 million. This slide displays our revenue and our gross margin over a longer period of time. As said, the reported gross margin in the quarter was 61% compared to 58% last year. As we can see on this graph, the gross margin is improving over time. However, fluctuations in the gross margin can be expected between periods as it is dependent on mainly two factors. One is the product mix, and the other one is the use of different sales channel partners. The purpose of this slide is to put C-RAD's growth journey into a context, and that is a context where investments have been made in the organization to support growth. This has, of course, generated an increase in operating expenses over time. This graph outlines operating expenses and revenue for the last four years, and where we can see that these investments, they are in fact paying off in the sense that the revenue trend line has a steeper upward leaning curve as compared to operating expenses. Equally meaning that the average yearly operating expense in relations to sales is going down. This slide shows our operating profit and revenue over a longer period of time. As seen, the business of C-RAD is volatile between the quarters and also expected to be so going forward, since larger single order has an effect in the quarter when they are delivered. The trend line clearly shows that C-RAD is on a growth journey, but the company also, since mid-2018, has reached an important milestone in the sense that the company's delivering not only growth, but profitable revenue growth, which significantly improved during the third and through the fourth quarter in 2020 and now continues in the first quarter of 2021. This slide displays, on the left-hand side, our balance sheet, and right-hand side, the cash flow statement for the first quarter with a couple of condensed comments to be made. First off, on the balance sheet, we have a relatively low level of immaterial assets. We are completely debt-free. We have a solidity of 77%. With regards to cash flow, we have a positive cash flow from our operations, we end the quarter with liquid funds amounting to SEK 112 million. On top of that, we have an unused credit facility of SEK 20 million. This slide displays our order backlog and how it has developed over the recent quarter. As I think you all know, the order backlog represents orders that have been received but not yet delivered nor invoiced. The backlog amounts to SEK 340 million at the end of the quarter, an increase of 30% compared to same period last year. From the total order backlog, about half relates to products and the other half relates to service contracts. Close to SEK 28 million of the order backlog will be recognized as revenue for service contracts within the coming 12-month periods, as service contracts are recognized as revenue over the contract period. The service contract can be up to eight years, while the most common contract period is three to five years. By that, I end the financial presentation, and I hand back to you, Priscilla. Thank you for the presentation, Henrik. We would like to inform you that as a consequence of the COVID-19 pandemic, the board of directors has decided that the annual general meeting shall be conducted without the physical presence of shareholders, proxies, and third parties, and that voting rights may only be exercised by postal voting before the annual general meeting. I now hand over the mic to Tim. Thank you, Priscilla. Let's move on. Our mission summarizes our overall goal. C-RAD's cutting-edge solutions ensure exceptionally high precision, safety, and efficiency in advanced radiation therapy, helping to cure more cancer patients and improve their quality of life. Cancer is among the leading causes of death worldwide. Three methods have been established to treat cancer, which is surgery, drug therapy or chemotherapy, and radiation therapy. C-RAD is active in the field of radiation therapy, and our products are used to improve patient safety and increase efficiency. The demand for our products is driven by the worldwide implementation of high-precision treatment techniques. I would like to start with the highlights from last year. Beginning of the year, C-RAD carried out the directed new share issue of 2.5 million shares, and we were raising proceeds of approximately SEK 108 million. Shortly after, COVID-19 affect the whole world and also C-RAD, of course. Measures were quickly taken to protect employees, maintain focus on our customers, and reduce cost. What happened, an former employee has filed a lawsuit for compensation, which is still ongoing. Several important customer orders have been secured last year despite the situation and despite the pandemic, and I would like to name a few of them. In China, we succeeded to receive an order from the Shenzhen Proton Therapy Center for several Catalyst systems. That was a project that we won together with the proton therapy company, IBA, from Belgium. A customer in Germany, in Berlin, has selected also the C-RAD solution to equip their LINAC fleet with surface tracking and implement high-precision radiation therapy with supporting positioning devices from C-RAD. Towards the end of the year, we received a large order from a partner in the U.S., for proton therapy as well, for several sites that have started to be implemented, and a few sites are still pending. Success in Australia, where several customers in the state of New South Wales selected C-RAD or C-RAD solution, as their surface tracking solution. Those installations are ongoing and implementation takes place as we go. Another proton project from China again, Shanghai Proton and Heavy Ion Hospital decided also for the C-RAD solution and implements currently the Catalyst system for their workflow. Another point worth mentioning is C-RAD and Elekta have expanded the cooperation. As you know, we cooperated already before last year, since 2019, with Elekta. There's a focus on the North American market, this cooperation has now been expanded to include also China. Coming to the financial highlights from last year. We are closing the year with a record order intake of close to SEK 313 million. This is reflecting a growth of 16% compared to 2019 full year. Despite all pandemic-related challenges, we were able to grow revenue by 8% on the full year side. I would like to mention here, I think the focus from customers on surface tracking was given. I think the challenges customers were experiencing, that is partly reflected in the revenue. Due to the pandemic, customers were closed down or governments closed down the country, installation could not proceed as planned. Still, 8% growth is a remarkable result. With a well-controlled cost structure, we succeeded to generate an operating profit of SEK 17.1 million, which reflects a profit margin of 7.7% for the full year 2020. This is a very positive development and underlines the demand for our technology, even in such turbulent years as 2020 certainly was. Especially the APAC region showed a very dynamic development also during 2020, measured in order intake, whereas the COVID-related measures were taken very early in the year by various governments. We achieved a recovery phase already during the summer. EMEA and especially the U.S., were affected much longer into the year. Despite that, we were able to deliver growth. I am very pleased with the result. However, most important is that continuously increasing demand for cancer care and the overall trend within radiation therapy towards high-precision treatments is creating an underlying growth for technology like ours. According to research, the RT market as a radiation therapy market is growing with approximately 7.8% annually until 2025. The driving factors are a global shortage of cancer care, an aging population, and improvements in the diagnostics. The clinical focus has shifted towards quality of life after the treatment, and high-precision therapy is becoming increasingly important. We are convinced that accurate patient positioning is on its way to become standard of care, and there are several indications for that. The majority of all tenders for new linear accelerators in the Western world include positioning products. Customers are asking to include positioning products in the offering. Major vendors of linear accelerators, Varian, Elekta, also Accuray, have all included in different ways and started to incorporate positioning products in their product catalog and in their offering towards the customer. The third point, the last technology within radiation therapy, which is proton therapy or proton or particle therapy, simply requires a degree of precision that requires also positioning product. That are three very strong indications that this technology is on its way to become standard of care. If we look at the market and the market opportunity, our focus is on the advanced markets within radiation therapy. Worldwide, there's an installed base of linear accelerators of around 12,000 units. If we focus on the advanced markets, we can say that roughly 9,000 out of the 12,000 are installed in these regions. If we follow the thought, this technology is becoming standard of care, we would say around 75% of the accelerators in the advanced market, sooner or later, will be equipped with surface tracking. We then take a look at the current market penetration from C-RAD, but also from other vendors in this space, we can say that roughly 20% of the market are already equipped with surface tracking. There is another 80%, or roughly 5,000, LINACs to go after. We take a closer look at our installed base, we have installed around 600+ systems worldwide. Here in this slide, the orange mark countries are the countries where we have installed systems. We then take a look at the 5,500 LINACs that are still to be equipped, we see an annual market potential of around SEK 1 billion. If we look at the implementation and the adoption of surface tracking over the last five years, what we see on this slide is the distribution of different cancer indication treated with radiation therapy at a given cancer centers in the U.S. We see that the different indication, the fluctuation between the different indications is basically minimal. Our expectation is also that this will remain unchanged for the foreseeable future. If we take a look at the table in the middle of this slide, it is basically showing the adoption of surface tracking in the year 2015 and also compares this with the year 2020. The clinical focus of surface tracking five years back was only on breast patients. This has expanded. Research at various universities has led and shown the advantages of using surface tracking for other indications as well. Now we can say that five indications where customers that have surface tracking are using the system for at least these five indications, maybe more. That reflects roughly 70% of the patient population that is getting treatment at the radiation therapy center. Also here, another indication for the surface tracking technology becoming standard of care. What are the advantages with the C-RAD solution? If you take a look on the clinical advantages, I think there are five points to be mentioned. It is dose free, it definitely cause less side effects compared to X-ray based systems. It's non-invasive, which creates an ease of use for the patient, of course, but more important even for the operator. It is markerless. Here, clearly an advantage for the patient. The patient comfort has highest priority there. It has less impact on the daily workflow. The C-RAD system is very well integrated into the clinical workflow, integrated in the treatment systems, and therefore is easy to operate, which clearly translates into usability advantages for the operator. Lastly, I would like to mention the patient compliance. We saw on the previous slide, the technology can be used on the majority of patients, and to support the treatment process for those patients. Taking a quick look at the C-RAD business model, I mentioned already that our focus is the advanced radiation therapy clinics, essentially worldwide. We are addressing those customers through three sales channels. The largest part is still our direct sales organization that is covering the major markets. In other markets, we have distributors, markets where we are not represented ourselves, we have distributors. I think the important part or the important sales channel is our industrial partners. The Elekta cooperation, for example, is falling into this bucket. I think here we see the largest growth rates over the last years. The C-RAD organization, the focus is on product management, of course, product development. As a med tech company, we have a pretty sophisticated quality and test department, marketing, sales, and service are in-house. All construction manufacturing related activities we have outsourced to contract suppliers in Finland. If you take a look at our team, Henrik mentioned already by the end of last year, we were around 60 employees in the organization. A very strong focus for us is the development of our products. We are working in a high-tech environment, 20% of our employees are directly related to the development activities. Taking a look at the service, we mentioned both from a business perspective, but also from building up the relationship on the long-term relationship with our customers, how important this is for our business in the long run. 33% of our employees are related to the service activities. Almost 30% related to sales and marketing, and then 20% are occupied with other activities. Looking at our strategy, service excellence is one of the key pillars of our overall strategy. We saw high growth rates over the past years, also in 2020, and revenue amounted to SEK 24 million only for the service business, with an order intake of SEK 80 million, reflecting a growth rate to the previous year of close to 40%. We consider the service business short-term, but also long-term, and especially long-term, to be an important contribution to our revenue stream. When we look at the attachment rates, we see a very clear pattern where in North America, essentially all systems are sold with a service contract. That might be that the service contract is sold at the point of sales when the customer's deciding on the product, but it might also be that the customer selects the service contract after the warranty has expired. In the EMEA region, we are above 60% attachment rate. APAC is slightly behind. If we speak about APAC, we need to take a closer look. Markets like Japan, Australia, usually customers go also with a service contract. In China, for example, customers are not yet at the position that they always sign up for service contracts. There it is. I finished my presentation. C-RAD ends the year 2020 with several positive factors for further success in terms of our compelling solutions and a high market potential, supported by a great team, a solid financial platform, and a record high order backlog. We are very proud of what we have achieved last year, and I want to take this opportunity to extend my appreciation to all the C-RAD employees for their great contribution during this very challenging year, but we still were successful. We can continue to expect volatility in individual quarters, and it is still unknown what further impact COVID-19 might have. I'm convinced that we will continue to see a growing demand for our solutions in high-precision radiation therapy. I'm very much looking forward to this new year. I'm closing the presentation with our financial calendar, but I want to specifically point attention to the left side of this slide. There are two investor presentations coming up end of May with ABG in Stockholm, and in September, beginning of September, C-RAD is going to present also at the Pareto Healthcare Conference. I want to close this presentation. I want to thank you for attending today's webcast and hand over the microphone back to Priscilla. Now we'll have the Q&A session. We already have some people who submitted some questions. I'll start with the first one. Can you elaborate on the potential on the existing installed base of LINACs? Sorry, the sound was a little bit bumpy. Could you just open the microphone and then the person that asked the question could perhaps- Yes. This person does not have a mic. Okay. Can you just repeat the question, please? Okay. Can you elaborate on the potential on the existing installed base of LINACs? I mean, for us, of course, there are two opportunities. One is to upgrade the installed base, also to sell in conjunction with larger projects, typically when the customer is replacing the linear accelerator or makes other larger investments, and C-RAD is part of the package. I think what we see is a very different pattern in the more private sectors. Investments are usually taken when there is the need or when customers see the need and the desire to have this technology, so they can act a little bit more freely to do these investments, and that is something what we see, for example, in North America. On the other hand, in Europe, the market is still dominated by public hospitals and publicly funded by the local governments. Usually, they are bound to a long-term budget process. Here we see more a pattern where customers are deciding for the C-RAD technology in conjunction with a replacement of the treatment system. Okay. We have a person who raised their hand. I'll just allow them to talk. Hello, can you hear us? Do you have your mic on? Sorry. Hello, is that me? Yes. Oh, okay. Sorry. Yeah. Just a couple of question quickly. Just on the pickup of order that you've seen in the U.S. and the continuation in China, I was just wondering if you could give us a sense of the market share of the new orders that you're having in the various region. The first question. The second one was, do you believe that Europe is sort of one quarter behind the U.S. or because we've seen more problems and it's been longer, that it's going to take a bit longer for European investment to catch up with what's happened in the U.S.? Then the third question was, I think you mentioned in your presentation that you were saying that the positioning market should be about SEK 1 billion. I don't know if you said roughly when you think that would be, and I know that that would be a creative forecast, but sort of sense of what share of that market in the long term you would assume to take. Thank you very much for the questions. The first question was related to the market share of the orders, and I assume now with market share you mean the split between the different vendors. I can't give you the exact numbers now, but I mean, it is still so that we in general are delivering to all vendors. Having the said, I think especially for the North American market, where we engage in this cooperation with Elekta, and this is turning out very successful. There we are leaning more towards systems that are installed on an Elekta machine. The second question was related to the delay in orders. If I understood the question right, it is related specifically to the European region and what we see there, I mentioned already earlier that in Europe, the majority of the hospitals are public hospitals or publicly funded hospitals. What we certainly see is that the decision-making process and the approval process of investments is getting longer. I think that is nothing what is only affecting C-RAD, but we see that also with other vendors in our space. It is not that the investments have been stopped, but the approval process has simply been becoming more complex, and therefore, it takes more time for the decision. I think that's also what we see reflected, especially on the order intake side. The third question was related to the market potential. I think where we are coming from is if we look at the total market, we believe that there is still around 5,000, 5,500 LINACs that are supposed to be equipped with surface tracking. If the assumption that it is standard of care, if we assume that C-RAD's technology will be installed on these LINACs for surface tracking, we believe that there are still 5,500 LINACs to be equipped. Having this said, over the next years, we will still see a ramp-up curve, I think this 1 million would be ultimately the annual market potential for all companies in that space. We come to the next. Okay. This next person who raised their hand, I'll just unmute them. Hello, Hans. I unmuted you. You can ask your question. Hello. Can you Can you hear me? Hello. Yes, we can hear you. [Non-English content] I think the connection is breaking a little bit. Could you just repeat your question? [Non-English content] Yes. [Non-English content] The STARLIT project was kicked off by various companies in cooperation with universities around Elekta, basically around MR-LINAC. C-RAD was contributing in this project actually on two angles, but the main focus for us was to explore the surface tracking technology in an MR environment and how surface tracking can contribute into the MR workflow. I don't want to go too deep now into the results. I think we found very interesting results as part of this research project, and that might have influence on our products moving forward. Okay. Thank you. Do we have any other questions? Priscilla? actually on two angles, but the main focus for us was to explore the surface tracking technology in an MR environment and how surface tracking can contribute into the MR workflow. I don't want to go too deep now into the results. I think we found very interesting results as part of this research project, and that might have influence on our products moving forward. Okay. Thank you. Do we have any other questions? Priscilla? actually on two angles, but the main focus for us was to explore the surface tracking technology in an MR environment and how surface tracking can contribute into the MR workflow. I don't want to go too deep now into the results. I think we found very interesting results as part of this research project, and that might have influence on our products moving forward. Okay. Thank you. Do we have any other questions? Priscilla? actually on two angles, but the main focus for us was to explore the surface tracking technology in an MR environment and how surface tracking can contribute into the MR workflow. I don't want to go too deep now into the results. I think we found very interesting results as part of this research project, and that might have influence on our products moving forward. Okay. Thank you. Do we have any other questions? Priscilla? actually on two angles, but the main focus for us was to explore the surface tracking technology in an MR environment and how surface tracking can contribute into the MR workflow. I don't want to go too deep now into the results. I think we found very interesting results as part of this research project, and that might have influence on our products moving forward. Okay. Thank you. Do we have any other questions? Priscilla? actually on two angles, but the main focus for us was to explore the surface tracking technology in an MR environment and how surface tracking can contribute into the MR workflow. I don't want to go too deep now into the results. I think we found very interesting results as part of this research project, and that might have influence on our products moving forward. Okay. Thank you. Do we have any other questions? Priscilla? Yes, we have more questions. Now I just hand over the mic to Oscar. You can ask your question. Hi. Thank you for your presentation. I have two questions to Tim initially, and that is how is the collaboration with Elekta progressing in Asia? I also would like to know if you can make any comments on the current dispute with the former employee. Towards Henrik, I would like to know whether the current cost base, can we expect a similar cost base the coming 12 months? Thank you. Do you want to start, Henrik? I can start off with the question on the cost base, and the rough answer on that is we are clearly on a growth journey as Tim has described. We have various factors supporting that growth, but one factor is, of course, further investments in our organization. We still expect that cost-wise, the investments in the organization will be lower than the growth in revenue. The short answer is, yes, you can expect it to go upwards, but over time, revenue will increase more, so putting more on the bottom line. Perfect. The other question was Elekta cooperation in Asia, to be precise. Right now, this is China, specific to China. I think, also what we have learned in the process of getting the cooperation implemented in the U.S., it takes some time to train and educate the sales organization, to align the messaging, to align the approach towards the customer. I think we made good progress. We have received the first orders out of this collaboration also in China. Having this said, there's of course still a way to go, and we, I think, see in North America, where it could take us. Also, there's still something to be done, but China simply started much later in this cooperation. I'm very optimistic. I think customers, in general, appreciate that. I think what is also very important, this approach of thinking of making this technology to standard of care. I think the customers like the idea that the vendors take a position and select one vendor as their partner. Customers are usually taking a decision for the next 10 years, and from that perspective, they also want to be reassured that compatibility is guaranteed over the next year. Okay. Sorry. The other question, the second question was related to the dispute with the former employee. I can't give much more details at this moment. The hearing is scheduled for end of this month. It starts on May 17th. Yeah, that's the only update I can give at this moment. Perfect. Thank you. Thank you. Priscilla, do we have more questions? Yes, we have more questions. We have Peter, who is trying to ask some questions, but they are in Swedish. I am just going to see if I can allow him to talk so he could ask his questions. Hello, Peter? Okay. Maybe he does not want to talk. If you can send your questions in English, then maybe I can read them out loud. We have some other questions from people who cannot use their mic. I can read out this one. When do you expect to have Catalyst+ version approved in all markets? Well, the major markets are already covered. We obtained CE approval, basically it is now a year ago, or CE clearance for the European market, the U.S. during last summer. These two major blocks are covered. The countries that typically have a longer lead time is China and Japan. In both countries, the approval process is ongoing. We do our best to do it as quickly as possible. I cannot give an exact date simply because it is not following a very, how should I say, a very clear and obvious time pattern. I am confident that next year we will have it cleared also in those markets. We have a following question. Can you comment a slight decrease in the number of employees? Is that a result of COVID-19 or other reasons? Yeah. C-RAD took active measures during last year, and that affected also some of our employees. That is the main reason, yes. We have one question. What's the plan with cash, SEK 111 million? Do you have any plans to buy other companies? That is certainly an option and the core reason for the rights share issue that was conducted a little bit more than a year ago, that was to add funds to the company to enable growth for the company, and that growth could be accomplished by investing in an organization or perhaps acquiring another company. That could be part of the agenda, yes. That said, not too many target companies within our space of technology. Again, yes, could be. Okay. We have this question, the next question. In the report, you state that you expect the product sales will continue to grow in a notably higher pace than the overall market. Could you give some flavor on how much the overall radiation therapy is estimated to grow the coming years to put your prediction into some context? The research that I was quoting here now in the presentation was foreseeing 7.8% annual growth rate. Okay. We have some final anonymous questions. It's about three questions. I'm going to read them out loud. You highlight a strong performance and development with Elekta in North America. Do you see the region in the future can become of similar importance as EMEA in terms of volume? In the first place, the North American market is reflecting roughly 40%, 45% of the global market. There is a significant opportunity in North America. There's no doubt about this. I think what we saw now for the first time in the first quarter this year, basically North America and APAC region were both roughly on the same level in terms of order intake, which is certainly a step forward compared to what we have seen before. I think what is important for us is to focus now on developing this market further, to utilize and work with our partners to develop the market and develop the marketing and the sales strategy even further, but at the same time also to continue working with our direct sales force towards the end customers. I think what we have also seen last year that the proton market gives us a good opportunity. I think C-RAD is well-recognized as a vendor for surface tracking for the proton market, and I think that's also something what customers see and understand. Let's say the dynamic in the proton sector in the U.S. currently is fairly good. You mentioned that the average delivery time for products in the quarter was seven months, which is slightly higher than usual. Is there anything particular behind this, and do you expect longer delivery times going forward? Thank you for that question. No, I would say there's nothing particular in that, but just taking a step back, during 2020, delivery times were actually a bit lower than usually, and the mechanics behind that was sort of that a lot of already ordered projects were stalled due to the pandemic coming as a great surprise and shock to everyone. Whereas orders that were placed. In 2020, during the pandemic, we're done with eyes wide open from the customer perspective. They placed the order and want the shipment fairly quick. That's why delivery times in 2020 were fairly low. What we see now in 2021, at least the first quarter, that we have been able to ship out a couple of older projects or orders in the order backlog, which essentially is a good thing, but that is what sort of mathematically drives that number up a little bit. Going forward, it's of course difficult to say exactly how the ongoing pandemic is going to play out in various regions. I would say that where we ended up now in Q1 and what we had in 2020, the average of those two is probably what we could expect for the foreseeable future. Okay. Can you elaborate on the development and reimbursements you are seeing and how these are driving the adoption of surface tracking? Well, in general, if we look at major markets, the implementation or adoption of high-precision radiation therapy is in general incentivized. As such, also surface tracking is one of the tools that are required to deliver these treatment or these techniques in a safe and efficient way. In some markets, in North America, for example, there are direct reimbursements, but otherwise, there are indirect reimbursements for investments in this technology. Okay. We have just two final questions that I received in the chat. Any plans to present C-RAD for investors outside Sweden? Well, among the larger investors, we have a few international investors as well. Yes, we have some investors from Europe mainland, but also from overseas. Yes. The focus is not now to make road shows abroad or target investors abroad, but I think Europe and Europe mainland is within reach for us. Okay. Now the final question. Are C-RAD going to try to buy the rest of the 50% of patent from Beamocular? If so, soon or later in future, and are bankruptcy trustee that part C-RAD shall negotiate with? That one is not pretty clear. If I may comment to the extent I can at the moment. The other 50% are owned by the bankrupt estate, and the other 50% are owned by C-RAD. At the moment, we have no active plans to take this any further. Having this said, plans might change over time, but I want to emphasize, this patent is related to the GEMini product, and this is nothing what we are actively pursuing from a development perspective as we speak. The focus of our organization and where we really see the opportunity in the market is related to our positioning products. Yeah, basically, that's also what we have presented here. The results are not related to GEMini, they are related to our positioning products. Okay. That's it for the questions. Perfect. I would like to take the opportunity to thank everyone for attending this webcast.